CBIO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 Oct 2023 @ 16:00):

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation...

Stats
Today's Volume	460 710
Average Volume	437 269
Market Cap	19.42M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0.240 ( 2023-01-13 )
Next Dividend	$0 ( N/A )
P/E	-0.0247
ATR14	$0.0370 (7.24%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Luo Ying	Buy	3 350 897	Stock Option (Right to Buy)
2023-10-30	Luo Ying	Buy	2 840 376	Common Stock
2023-11-20	Luo Ying	Buy	2 262 755	Stock Option (Right to Buy)
2023-11-20	Ye Weiguo	Buy	1 665 115	Stock Option (Right to Buy)
2023-11-20	Ma Songjiang	Buy	4 510 047	Stock Option (Right to Buy)

INSIDER POWER
23.99
Last 85 transactions
Buy: 88 748 347 \| Sell: 111 334 812

Volume Correlation

Long: -0.02 (neutral)

Short: -0.30 (neutral)

Signal:(55.246) Neutral

Catalyst Biosciences Inc Correlation

10 Most Positive Correlations
CALA	0.925
ODT	0.917
UPC	0.909
BCAB	0.908
NBIX	0.897
LLNW	0.891
ENNV	0.891
LFMD	0.891
XPDI	0.889
YJ	0.889

10 Most Negative Correlations
SHC	-0.922
WYNN	-0.921
DSPG	-0.917
ACLS	-0.913
PPD	-0.908
BNIX	-0.907
DUNE	-0.906
RVNC	-0.902
HHGC	-0.901
FWONK	-0.899

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Catalyst Biosciences Inc Correlation - Currency/Commodity

0.70
( moderate )

0.65
( weak )

0.00
( neutral )

0.73
( moderate )

-0.14
( neutral )

-0.41
( neutral )

Catalyst Biosciences Inc Financials

Annual	2022
Revenue:	$794 000
Gross Profit:	$-4 000.00 (-0.50 %)
EPS:	$-0.260

FY	2022
Revenue:	$794 000
Gross Profit:	$-4 000.00 (-0.50 %)
EPS:	$-0.260

FY	2021
Revenue:	$0.00
Gross Profit:	$-7.38M (0.00 %)
EPS:	$-2.87

FY	2020
Revenue:	$20.95M
Gross Profit:	$11.79M (56.26 %)
EPS:	$-2.93

Financial Reports:

No articles found.

Catalyst Biosciences Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$1.430 (N/A)	$0 (N/A)	$0.240 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Catalyst Biosciences Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0.994 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$59.77	2015-08-20
Last Dividend	$0.240	2023-01-13
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$61.44	--
Avg. Dividend % Per Year	39.53%	--
Score	4.37	--
Div. Sustainability Score	0
Div.Growth Potential Score	0.994
Div. Directional Score	0.460	--

Next Divdend (Est)
(2027-07-05)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

4.37

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2015	$59.77	22.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$1.430	143.00%
2023	$0.240	41.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	55.72	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	-0.709	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	12.04	1.500	10.00	10.00	[0.1 - 1]
payoutRatioTTM	-0.289	-1.000	-2.89	2.89	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-71.39	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.352	2.00	-0.117	-0.235	[0 - 30]
freeCashFlowPerShareTTM	-0.352	2.00	-0.176	-0.352	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	3.15	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	55.75	1.000	10.00	10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	-0.0127	0.800	-3.42	-2.73	[0.5 - 2]
Total Score				-0.0749

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.439	1.000	-0.145	0	[1 - 100]
returnOnEquityTTM	12.04	2.50	10.00	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.352	2.00	-0.117	-0.352	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.352	2.00	-0.117	-0.235	[0 - 30]
payoutRatioTTM	-0.289	1.500	-2.89	2.89	[0 - 1]
pegRatioTTM	-0.0114	1.500	-3.41	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	16.85	1.000	10.00	0	[0.1 - 0.5]
Total Score				0.994

Catalyst Biosciences Inc

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.